Faculty of Life Sciences, The University of Manchester, 46 Grafton Street, Manchester M13 9NT, United Kingdom.
Int J Cardiol. 2013 Oct 9;168(4):3506-13. doi: 10.1016/j.ijcard.2013.04.210. Epub 2013 Jun 3.
Alterations in coronary vasomotor tone may participate in the pathogenesis of acute myocardial infarction (AMI). Vascular ATP-sensitive K(+) (KATP) channels, formed by Kir6.x/SUR2B, are key regulators of coronary tone and mutations in cardiac (Kir6.2/SUR2A) KATP channels result in heart disease. Here we explore the pathophysiological mechanism of a rare mutation (V734I) found in exon 17 of the ABCC9 gene, estimated to cause a 6.4-fold higher risk of AMI before the age of 60.
Eleven patients carrying the mutation were identified; they presented AMI of vasospastic origin associated with increased plasma levels of endothelin-1 and increased leukocyte ROCK activity. The effects of the mutation on the functional properties of the two splice variants of ABCC9 (SUR2A and SUR2B) were studied using patch-clamp electrophysiology. The mutation reduced the sensitivity to MgATP inhibition of Kir6.2/SUR2B channels but not of Kir6.2/SUR2A and Kir6.1/SUR2B channels. Furthermore, the stimulatory effects of MgNDP (MgADP, MgGDP and MgUDP) were unaltered in mutant Kir6.2/SUR2A and Kir6.1/SUR2B channels. In contrast, mutant channels composed of Kir6.2 and SUR2B were less sensitive to MgNDP activation, assessed in the presence of MgATP. The antianginal drug nicorandil activated Kir6.2/SUR2B-V734I channels, thus substituting for the loss of MgNDP stimulation, suggesting that this drug could be of therapeutic use in the treatment of AMI associated with V734I.
The 734I allele in ABCC9 may influence susceptibility to AMI by impairing the response of vascular, but not cardiac, KATP channels to intracellular nucleotides. This is the first human mutation in an ion channel gene to be implicated in AMI.
冠状动脉血管舒缩功能障碍可能参与急性心肌梗死(AMI)的发病机制。由 Kir6.x/SUR2B 构成的血管三磷酸腺苷敏感钾(KATP)通道是冠状动脉张力的关键调节剂,而心脏(Kir6.2/SUR2A)KATP 通道的突变可导致心脏病。在这里,我们探讨了 ABCC9 基因外显子 17 中发现的一种罕见突变(V734I)的病理生理机制,该突变估计会使 60 岁前发生 AMI 的风险增加 6.4 倍。
共鉴定出 11 例携带该突变的患者,他们表现为血管痉挛性 AMI,伴有内皮素-1 血浆水平升高和白细胞 ROCK 活性增加。使用膜片钳电生理学研究了该突变对 ABCC9 两种剪接变体(SUR2A 和 SUR2B)的功能特性的影响。该突变降低了 Kir6.2/SUR2B 通道对 MgATP 抑制的敏感性,但对 Kir6.2/SUR2A 和 Kir6.1/SUR2B 通道没有影响。此外,突变型 Kir6.2/SUR2A 和 Kir6.1/SUR2B 通道中,MgNDP(MgADP、MgGDP 和 MgUDP)的刺激作用没有改变。相比之下,在存在 MgATP 的情况下,由 Kir6.2 和 SUR2B 组成的突变型通道对 MgNDP 的激活作用不敏感。抗心绞痛药物尼可地尔激活了 Kir6.2/SUR2B-V734I 通道,从而替代了 MgNDP 刺激的丧失,这表明该药物可能对治疗与 V734I 相关的 AMI 有治疗作用。
ABCC9 中的 734I 等位基因可能通过损害血管而非心脏 KATP 通道对细胞内核苷酸的反应,从而影响 AMI 的易感性。这是第一个与 AMI 相关的离子通道基因突变。